Oncolytics Biotech Inc.
ONC.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -33.04M | -28.51M | -25.95M | -22.49M | -23.34M |
| Total Depreciation and Amortization | 14.30K | 17.30K | 14.80K | 24.30K | 28.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.80M | 7.39M | 5.45M | 1.99M | 1.49M |
| Change in Net Operating Assets | 614.80K | 1.05M | 370.80K | 1.66M | 1.97M |
| Cash from Operations | -22.61M | -20.05M | -20.11M | -18.82M | -19.85M |
| Capital Expenditure | -12.00K | -7.00K | -18.20K | -36.60K | -149.90K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -12.00K | -7.00K | -18.20K | -36.60K | -149.90K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 20.20K | 20.20K | -30.60K | -9.60K | 27.40K |
| Issuance of Common Stock | 21.14M | 17.61M | 17.25M | 13.10M | 8.94M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.15M | -1.04M | -785.50K | -971.50K | -250.50K |
| Cash from Financing | 17.39M | 13.96M | 13.81M | 10.68M | 8.24M |
| Foreign Exchange rate Adjustments | 122.60K | 263.60K | -927.60K | -1.26M | -665.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.11M | -5.83M | -7.25M | -9.45M | -12.43M |